Friday, June 13, 2014

New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access

http://www.itpcmena.org/IMG/pdf/new_treatment_for_hepc__strategies_for_achieving_universal_access_en.pdf

New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access



New Treatments for Hepatitis C Virus: Strategies for ...

www.aidsportal.org/web/guest/resource?id=6b3acf6a-14a0-4e33...
Mar 19, 2014 - New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access. By Pauline Londeix, technical advisor to M├ędecins du Monde, ...
[PDF]

Download the Full Report here - ITPC-MENA

www.itpcmena.org/.../new_treatment_for_hepc__strategies_for_achievin...
by P Londeix - ‎2014
Mar 4, 2014 - Strategies for Achieving. Universal Access .... pharmaceutical companies, universal access would be prac- tically unachievable, even in .... expanding access to new HCV treatments, and compares them in order to determine ...
===============================

Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C

Forbes - ‎Jun 9, 2014‎
Wall Street has already declared a winner in the race to develop new treatments for hepatitis C, a virus that infects 3.2 million Americans that is the leading cause of liver transplantation in the United States. It's Gilead Sciences. Everyone knows that Gilead's Sovaldi, already the best drug ... It's just impossible.” Gilead hopes to launch a three-drug, one-pill hepatitis C treatment this fall, and is expected to mop up a huge number of hepatitis C patients. Already, Sovaldi's rapid uptake in usage has led to protests from ... 

Merck & Co to buy Idenix to boost hepatitis C drugs portfolio

Reuters - ‎Jun 9, 2014‎
The payoff for Merck could come from a triple therapy that may cure patients with all genotypes, or strains, of the hepatitis C virus in as little as four to six weeks, its research chief, Roger Perlmutter, said in an interview. "An ideal therapy ... In a recent mid-stage trial, Merck's two-drug combo cured 98 percent of previously untreated patients with genotype 1, the most common and hardest to treat variant of hepatitis C. The Idenix drug in .... Bankruptcy Law · California Legal · New York Legal · Securities Law. Support & ...

Merck & Co. to Buy Hepatitis-Drug Maker Idenix

Bloomberg - ‎Jun 9, 2014‎
Buying the Cambridge, Massachusetts-based company will help Merck in the competition to develop a daily, all-oral regimen that treats different strains of the viral infection and doesn't include ribavirin, a standard therapy for hepatitis C that has serious side effects. In April, Merck said its once-a-day hepatitis C pill, which combined two drugs, stopped ... Merck shares gained less than 1 percent to $57.94 at the close in New York. Idenix shares more than tripled to $23.79. Idenix came to Merck after another company ...

Merck Bids $3.8 Billion for an Edge in Hepatitis

New York Times - ‎Jun 9, 2014‎
New drugs are transforming the treatment of hepatitis C, replacing injections with pills, as well as increasing the cure rates, reducing side effects and cutting the duration of treatment to as little as eight to 12 weeks from as long as a year. But the new pills for ... to 18 weeks of treatment. Adding a drug from Idenix to those two drugs could allow for a once-a-day pill that could treat all subtypes of the virus in as little as four weeks, Dr. Roger Perlmutter, who heads research and development for Merck, said in an interview.

Merck to buy Idenix for $3.9 billion for Hepatitis C

NorthJersey.com - ‎Jun 9, 2014‎
based company will help Merck in the race to develop a daily, all-oral regimen that treats different strains of the viral infection and doesn't include ribavirin, a standard treatment for hepatitis C that has serious side effects. In April, Merck ... "The big pharma companies understand that the prevalence of people with hep-C is so big that the market is going to be around for the next 10 years," said Jason Kolbert, senior managing director with Maxim Group LLC in New York, in a telephone interview Monday. "It's a very fair ...

Merck agrees to buy Idenix for $3.85 billion

USA TODAY - ‎Jun 9, 2014‎
Drug companies are racing to test new and potentially lucrative treatments for hepatitis C. An estimated 3 million people in the USA are chronically infected with hepatitis C, the nation's leading cause of liver cancer and liver transplants. About half or more of ... It has three drugs in clinical development to treat the hepatitis C virus, known as HCV. Merck's ... The addition of the Idenix portfolio to our breakthrough treatments already under development brings us one step closer to achieving this goal." The Centers for ...

Merck to buy hepatitis C treatment maker Idenix Pharma

The Globe and Mail - ‎Jun 9, 2014‎
based Idenix – seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals. Hepatitis C has become one of the hottest categories in drug research as companies ...

Merck to Pay $3.85B for Hepatitis C Drug Developer

ABC News - ‎Jun 9, 2014‎
Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy without injections and debilitating side effects. Some have had their promising candidates fail after extensive testing, due to dangerous side effects, but Gilead Sciences Inc. ... Three Idenix experimental drugs have reached human testing and one, samatasvir, is in mid-stage testing. It's in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs ...

UPDATED: Merck scoops up troubled Idenix's hep C drugs in $3.85B buyout

FierceBiotech - ‎Jun 9, 2014‎
Eight months after it promised to go on a shopping spree for new experimental drugs, Merck ($MRK) has come up with a $3.85 billion cash deal to buy out Idenix, a biotech company best known for its setbacks in hepatitis C drug research. The deal instantly broadens Merck's ... Hepatitis C was once one of the hottest fields in biotech for M&A, but the deal-making cooled dramatically over the past two years as Gilead surged forward and other companies experienced setbacks. This morning, though, the focus is back on ...

Merck to buy Cambridge's Idenix in $3.85b deal

Boston Globe - ‎Jun 10, 2014‎
The pharmaceutical giant Merck & Co. agreed on Monday to pay $3.85 billion for a Cambridge biotech that is developing drugs to cure hepatitis C, a staggering price for a small company with fewer than 100 employees. Merck's agreement to buy 16-year-old Idenix Pharmaceuticals Inc. is the latest sign the Boston-area biotechnology cluster has become a powerful magnet for global drug makers in search of breakthrough medicines — and huge profits. Continue reading .... 1/28/14: Abby fight may be with mediocrity.

Investors eye Achillion for next big pharma deal

CNBC.com - ‎Jun 11, 2014‎
While AbbVie, Bristol-Myers and J&J are in the race with Merck and Gilead to develop new treatments for hepatitis C, a market estimated to be worth more than $20 billion in 2018, those three companies are left without nucs, Bayko noted. Nucs are considered to be a key ... $1B profit on Idenix deal. The goal among drugmakers now is to develop a single pill that patients can take once a day, with fewer side effects, that will cure the virus for all patients in the shortest period of time—potentially in a matter of weeks.

No comments:

Post a Comment